#Women-Health

2 stories

Clinical Trials June 20, 2026 · View digest

EndoCyclic Therapeutics ENDO-205 IND Cleared March 23, 2026: First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis Designed to Eliminate Lesions Rather Than Suppress Symptoms

EndoCyclic Therapeutics announced FDA clearance of the Investigational New Drug (IND) application for ENDO-205 on March 23, 2026. ENDO-205 is a first-in-class non-hormonal precision peptide therapeutic for endometriosis, designed to eliminate lesions rather than modulate hormones — distinguishing it from all currently approved endometriosis therapies, which are either oral GnRH antagonists (elagolix, relugolix) or hormonal contraceptives. In preclinical models, ENDO-205 eliminated endometriosis lesions and associated inflammation with no safety signals in GLP toxicology studies. The Phase 1 will enroll healthy pre-menopausal women of reproductive age. Endometriosis affects roughly 10% of women of reproductive age globally, with a 6-10 year average diagnostic delay and no curative therapy.

Clinical Trials May 12, 2026 · View digest

Novo Nordisk ECO 2026 (May 12): Wegovy Weight Loss Independent of Menopausal Stage + 34,000-Woman Real-World Database Shows 42-45% Migraine and 25% Depression Risk Reduction

A second post-hoc analysis of STEP UP presented Tuesday found Wegovy 7.2 mg delivered consistent weight loss across reproductive life stages: 22.6% premenopausal, 19.7% perimenopausal, 19.8% postmenopausal, with 41.4% of premenopausal women hitting ≥25% loss. Waist-circumference reductions: 17.5%, 15.6%, 15.3% respectively. Separately, a real-world analysis of 34,000+ women showed that those taking Wegovy had a 42-45% lower migraine risk and a 25% lower depression risk starting six months in versus those on menopausal hormone therapy alone. The real-world data lands as observational signals that warrant prospective study — not as proof of causation — but reinforces the cardiovascular and quality-of-life narrative for the women's-health subgroup.